AVEO Oncology announces TIVO-3 trial topline results

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AVEO Oncology announced the presentation of data from the phase III TIVO-3 study of tivozanib (Fotivda) versus sorafenib in refractory advanced or metastatic renal cell carcinoma.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The California Institute for Regenerative Medicine, a state agency tasked with awarding billions of dollars of scientific funding for stem cell and gene therapy, has rescinded a controversial policy that was disrupting the flow of funding to cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login